CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics - Wikidata - awgldk - TriplyDB

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics

http://www.wikidata.org/entity/Q21090521

about

Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: principles, hopes, and challenges In vivo binding and retention of CD4-specific DARPin 57.2 in macaques Combined inhibition of caspase 3 and caspase 7 by two highly selective DARPins slows down cellular demise Signal peptide-binding drug as a selective inhibitor of co-translational protein translocation AnkPlex: algorithmic structure for refinement of near-native ankyrin-protein docking.Antiviral activity of recombinant ankyrin targeted to the capsid domain of HIV-1 Gag polyprotein.Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies Crystal structure of an antiviral ankyrin targeting the HIV-1 capsid and molecular modeling of the ankyrin-capsid complex.Combined Antiviral Therapy Using Designed Molecular Scaffolds Targeting Two Distinct Viral Functions, HIV-1 Genome Integration and Capsid Assembly Delineating CD4 dependency of HIV-1: Adaptation to infect low level CD4 expressing target cells widens cellular tropism but severely impacts on envelope functionality.Discovery and Characterization of a Novel CD4-Binding Adnectin with Potent Anti-HIV Activity.Conformation-dependent recognition of HIV gp120 by designed ankyrin repeat proteins provides access to novel HIV entry inhibitors.Human Immunodeficiency Virus Immune Cell Receptors, Coreceptors, and Cofactors: Implications for Prevention and Treatment.Tracing HIV-1 transmission: envelope traits of HIV-1 transmitter and recipient pairs Improved virus neutralization by plant-produced anti-HIV antibodies with a homogeneous beta1,4-galactosylated N-glycan profile.Antibody mimetics: promising complementary agents to animal-sourced antibodies.Human immunodeficiency virus type 1 escape from cyclotriazadisulfonamide-induced CD4-targeted entry inhibition is associated with increased neutralizing antibody susceptibility.Off-target-free gene delivery by affinity-purified receptor-targeted viral vectors.Current Peptide and Protein Candidates Challenging HIV Therapy beyond the Vaccine Era.Alpha-helicoidal HEAT-like Repeat Proteins (αRep) Selected as Interactors of HIV-1 Nucleocapsid Negatively Interfere with Viral Genome Packaging and Virus Maturation.Phenotypic deficits in the HIV-1 envelope are associated with the maturation of a V2-directed broadly neutralizing antibody lineage.Antibody Mimetics, Peptides, and Peptidomimetics.Non-Antibody Scaffolds as Alternative Therapeutic Agents

P2860

Q26995399-621233A2-EA8B-49B4-8C3E-7808CBA489A5 Q27320871-6CA9E54B-A5DC-46EB-88C8-6FE845D0DA61 Q27690122-0EC64C83-F8E2-404A-B27F-034374AEF54D Q28542401-26237D26-9097-4DFA-98F7-B53E92406B2D Q33577015-594C7B39-472D-4AFA-A4CB-0700C3C64340 Q34163977-455166DC-47DA-4A1A-BA09-0D4A23904BAD Q34229664-96F53E14-7C2E-42E6-8C7E-F99133830F3A Q35201628-61501AF4-7184-467C-B7A7-4EA44A54B4BA Q36030091-DAD0760D-F819-406B-B693-07A42F221549 Q36298503-4907ECF6-6C7D-459D-951E-A6DEE546EF88 Q36393594-F33D1685-C11F-4694-B82E-1FCDE501D06B Q36827348-E6F3350B-6067-4D82-8931-E330ED7C2202 Q37102101-4C9E2E4A-EF02-44DA-81C8-AC230063BA4D Q37233074-CA2322FD-2D0A-4773-A317-2DB08A380236 Q37343940-D5C8C088-255D-43ED-8E07-CE5F01480835 Q38255176-AB6096CB-578C-46C1-91DC-AA1F3B491259 Q39830543-192AEC99-7083-4004-868F-6CB6A594D38B Q41493938-2224E172-A230-430F-BF17-4B58A78BA00E Q41928050-46C165C8-CE10-4BE9-B0E4-52B81FBFB0DD Q45324180-63765C27-E944-45E4-8DD8-C73F33A565D8 Q47548910-B3C7529F-F36C-4E26-9DE8-B7841C73FF9D Q50981072-5362B0A0-B4E5-471B-9716-BC87EB8EB91F Q57260221-8BB6825D-6E6D-404E-9C9B-297CE99FFF1F

P2860

CD4-specific designed ankyrin repeat proteins are novel potent HIV entry inhibitors with unique characteristics

http://www.wikidata.org/entity/Q21090521

description

2008 nî lūn-bûn

@nan

2008 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2008 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2008年の論文

@ja

2008年論文

@yue

2008年論文

@zh-hant

2008年論文

@zh-hk

2008年論文

@zh-mo

2008年論文

@zh-tw

2008年论文

@wuu

name

CD4-specific designed ankyrin ...... rs with unique characteristics

@ast

CD4-specific designed ankyrin ...... rs with unique characteristics

@en

CD4-specific designed ankyrin ...... rs with unique characteristics

@en-gb

CD4-specific designed ankyrin ...... rs with unique characteristics

@nl

type

label

CD4-specific designed ankyrin ...... rs with unique characteristics

@ast

CD4-specific designed ankyrin ...... rs with unique characteristics

@en

CD4-specific designed ankyrin ...... rs with unique characteristics

@en-gb

CD4-specific designed ankyrin ...... rs with unique characteristics

@nl

altLabel

CD4-Specific Designed Ankyrin ...... rs with Unique Characteristics

@en

prefLabel

CD4-specific designed ankyrin ...... rs with unique characteristics

@ast

CD4-specific designed ankyrin ...... rs with unique characteristics

@en

CD4-specific designed ankyrin ...... rs with unique characteristics

@en-gb

CD4-specific designed ankyrin ...... rs with unique characteristics

@nl

P1433

Q21090521-13E00DFD-19FF-49AA-9673-C5D50B420AB1

P1476

Q21090521-57F30BDD-E665-4DCA-8F15-BFC05B58D558

P2093

Q21090521-2921C4E6-9493-473C-B515-F384D0F0D15A

Q21090521-31099757-BA53-4126-BECE-F888805A1587

Q21090521-3217641E-56DD-49FD-8FD6-7609C5BB5A34

Q21090521-467F6648-D016-4AAF-8B88-F1C0BCC17FD4

Q21090521-52A524B7-E508-4C42-BAA2-C44086518A31

Q21090521-6DDEA0EE-6170-4FD2-8352-F650CD6341CD

Q21090521-6F956AD9-90D8-4C92-8EDE-FDC5DE47B688

Q21090521-873E6DFB-C223-4885-9A66-85AFCF434393

Q21090521-A47CFC0C-AFC1-40CB-A4A2-D04A0DB0C3BA

Q21090521-C3D88421-3BFD-4AE9-8625-8A8FDF84C161

P2860

Q21090521-00B2CDC3-9E61-4164-B4EE-66733C0489CB

Q21090521-05F58899-767E-44D9-9BE5-A20BACCD6FE0

Q21090521-0A43AACB-9646-4475-A3E4-EB98717AD143

Q21090521-0A9DC6EB-46A0-4BE2-A25F-F437495018F7

Q21090521-0C053434-396A-4D25-9F5F-AD5EB09E6BEC

Q21090521-0CE8BFEE-5D05-4BC3-99E4-892C4B9B3384

Q21090521-0EB01239-6629-494B-A7C0-340C5A74EE8B

Q21090521-0F162F74-89CF-4C23-A7F8-E7817906E92E

Q21090521-11908641-D3E0-4DB5-985D-3D470EB8F8B0

Q21090521-139EC449-DB04-413D-8455-EAB7A291976E

P304

Q21090521-3F43AF27-7896-4E55-A889-3707DBB946EC

P31

Q21090521-87EC8F6B-ABB2-43E6-BA64-7FFFB27B9658

P3181

Q21090521-B52F2D90-06F9-4ED8-9E6B-46802580F7C1

P356

Q21090521-192ADB8D-503B-4BCB-9F36-C4A5FE2B498F

P407

Q21090521-200132CB-88CD-4C8E-8407-FACEE40217A7

P433

Q21090521-92D9B05C-B59F-408B-ABCB-4CDA91AB1E69

P478

Q21090521-9E699BA5-548C-4C36-9B80-EA3459E37B6F

P50

Q21090521-096F5625-E05A-4FEC-8DFA-146E33B11B51

Q21090521-DD120644-8221-497F-84D2-298ED26C04E9

P577

Q21090521-B24CA0AE-7D15-4FF0-AD49-3F709F36C9C1

P5875

Q21090521-8F4EA870-B15D-412A-BF76-EC3919F7EBCF

P698

Q21090521-FF81D041-1F5F-440E-93A3-FCED8D7BDF93

P921

Q21090521-B43E0BDE-7641-4C55-A056-5352D7D8F498

Q21090521-EC043751-4EF5-476F-BF09-AD4912EED4AD

P932

Q21090521-D02878A0-D3FB-4AAA-BB81-DB33455C20FA

P3181

P356

JOURNAL.PPAT.1000109

P1433

P1476

CD4-specific designed ankyrin ...... rs with unique characteristics

@en

P2093

Andreas Schweizer

http://www.w3.org/2001/XMLSchema#string

Axel Mann

http://www.w3.org/2001/XMLSchema#string

Claudia R Ruprecht

http://www.w3.org/2001/XMLSchema#string

Livia Berlinger

http://www.w3.org/2001/XMLSchema#string

Marek Fischer

http://www.w3.org/2001/XMLSchema#string

Melissa Robbiani

http://www.w3.org/2001/XMLSchema#string

Meropi Aravantinou

http://www.w3.org/2001/XMLSchema#string

Patrick Amstutz

http://www.w3.org/2001/XMLSchema#string

Peter Rusert

http://www.w3.org/2001/XMLSchema#string

Stéphanie Corthésy

http://www.w3.org/2001/XMLSchema#string

P2860

Designed to be stable: crystal structure of a consensus ankyrin repeat protein

In vitro selection and evolution of functional proteins by using ribosome display

Drug export pathway of multidrug exporter AcrB revealed by DARPin inhibitors

Directed in vitro evolution and crystallographic analysis of a peptide-binding single chain antibody fragment (scFv) with low picomolar affinity

A designed ankyrin repeat protein evolved to picomolar affinity to Her2

Inhibition of caspase-2 by a designed ankyrin repeat protein: specificity, structure, and inhibition mechanism

Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America

Determination of lymphocyte division by flow cytometry

High-affinity binders selected from designed ankyrin repeat protein libraries

Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody

P304

e1000109

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3680098

http://www.w3.org/2001/XMLSchema#string

P356

10.1371/JOURNAL.PPAT.1000109

http://www.w3.org/2001/XMLSchema#string

P407

P433

7

http://www.w3.org/2001/XMLSchema#string

P478

4

http://www.w3.org/2001/XMLSchema#string

P50

Alexandra Trkola

Stuart G Turville

P577

2008-07-25T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51427895

http://www.w3.org/2001/XMLSchema#string

P698

18654624

http://www.w3.org/2001/XMLSchema#string

P921

P932

2453315

http://www.w3.org/2001/XMLSchema#string